Essilor : Expiration of the Liquidity Contract
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130131:nBw315984a CHARENTON-LE-PONT, France--(Business Wire)-- Regulatory News : Essilor (Paris:EI) announces the expiration as of January 24, 2013 of the liquidity contract signed with CA Cheuvreux. The Company`s liquidity account included the following cash and Company common shares at this date: * 0 shares * € 11,857,851.92 As a reminder, the Company`s liquidity account included the following means at December 31, 2012: * 0 shares * € 11,864,433.09 About Essilor The world`s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates around €150 million to research and development every year, in a commitment to continuously bring new, more effective products to market. Essilor`s flagship brands are Varilux®, Crizal®, Definity®, Xperio®, Optifog and Foster Grant®. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of €4.2 billion in 2011 and employs around 48,700 people in some 100 countries. It operates 19 plants, a total of 390 prescription laboratories and edging facilities, as well as several research and development centers around the world. For more information, please visit www.essilor.com. The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP. Essilor Investor Relations and Financial Communications Phone: +33 (0)1 49 77 42 16 Copyright Business Wire 2013